In an open-label SUSTAIN 7 clinical trial published in the LANCET, 1,201 patients were randomly assigned to one of four treatment groups: semaglutide 0.5 mg (301 patients), dulaglutide 0.75 mg (299 patients), semaglutide 1.0 mg (300 patients), and dulaglutide 1.5 mg (299 patients)
[1] This reflux could theoretically result in a bitter or metallic taste in the mouth, particularly when lying down or after meals, though this connection requires further study
The pricing advantage reflects supply chain efficiency, not reduced quality
It carries out many bodily processes such as tissue development, growth, and repair
doi: 10.1016/j.cmet.2019.07.013 61 KohnkeSLamBBullerSZhaoCNuzzaciDTadrossJet al